Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise reduced its stake in Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 11.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,449 shares of the medical research company’s stock after selling 1,717 shares during the period. Banque Cantonale Vaudoise’s holdings in Quest Diagnostics were worth $1,639,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Pacifica Partners Inc. purchased a new stake in Quest Diagnostics in the third quarter valued at approximately $25,000. NBC Securities Inc. purchased a new stake in shares of Quest Diagnostics in the 3rd quarter valued at $25,000. Park Place Capital Corp lifted its stake in Quest Diagnostics by 73.4% during the 2nd quarter. Park Place Capital Corp now owns 189 shares of the medical research company’s stock worth $27,000 after acquiring an additional 80 shares in the last quarter. Chilton Capital Management LLC purchased a new position in Quest Diagnostics during the 1st quarter valued at about $28,000. Finally, FinTrust Capital Advisors LLC grew its position in Quest Diagnostics by 1,100.0% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 264 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. 87.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on DGX. Citigroup raised their price objective on shares of Quest Diagnostics from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, December 11th. Bank of America upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $140.00 to $160.00 in a research note on Tuesday, December 12th. Piper Sandler lifted their target price on Quest Diagnostics from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Monday, November 6th. Truist Financial cut their price target on Quest Diagnostics from $150.00 to $145.00 and set a “hold” rating on the stock in a report on Friday. Finally, JPMorgan Chase & Co. lifted their price objective on Quest Diagnostics from $148.00 to $149.00 and gave the company a “neutral” rating in a research note on Friday, November 17th. Eight analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $146.10.

Read Our Latest Stock Analysis on Quest Diagnostics

Quest Diagnostics Stock Down 1.7 %

Quest Diagnostics stock opened at $125.00 on Monday. The stock has a 50 day moving average of $135.28 and a two-hundred day moving average of $132.03. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $148.91. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of 16.69 and a beta of 0.92. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.70.

Quest Diagnostics (NYSE:DGXGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.04. The firm had revenue of $2.29 billion during the quarter, compared to the consensus estimate of $2.25 billion. Quest Diagnostics had a return on equity of 15.79% and a net margin of 9.23%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the company earned $1.98 earnings per share. As a group, research analysts expect that Quest Diagnostics Incorporated will post 8.82 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 22nd. Investors of record on Monday, April 8th will be paid a $0.75 dividend. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Friday, April 5th. This represents a $3.00 annualized dividend and a dividend yield of 2.40%. Quest Diagnostics’s dividend payout ratio (DPR) is 37.92%.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.